betaxolol ( kerlon , 8 ) was found to exhibit an appropriate preclinical pharmacological and human pharmacokinetic profile ( elevated oral bioavailability and prolonged plasma half-life ) for the treatment of chronic cardiovascular diseases such as hypertension and angina .
C0005320
betaxolol
C0020538
hypertension